株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性腎障害 : パイプライン分析

Diabetic Nephropathy - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 192557
出版日 ページ情報 英文 250 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
糖尿病性腎障害 : パイプライン分析 Diabetic Nephropathy - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 250 Pages
概要

糖尿病性腎障害とは、糖尿病による発症する腎臓の損傷を指します。疾患の主な特徴としてアルブミン尿や、糸球体濾過率の低下、高血圧などがあります。疾病素質には、肥満症や高血圧、高脂血・高糖血、喫煙などがあります。薬物両用や食生活改善などで症状が緩和する可能性があります。

当レポートでは、世界各国での糖尿病性腎障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性腎障害の概要

治療薬の開発

  • 糖尿病性腎障害向けパイプライン製品:概要
  • 糖尿病性腎障害向けパイプライン製品:比較分析

各企業で開発中の糖尿病性腎障害治療薬

大学/研究機関で研究中の糖尿病性腎障害治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

糖尿病性腎障害治療薬:開発中の製品の一覧(企業別)

糖尿病性腎障害治療薬:研究中の製品の一覧(大学/研究機関別)

糖尿病性腎障害治療薬の開発に従事している企業

  • AbbVie Inc.
  • Antisense Therapeutics Limited
  • Arena Pharmaceuticals, Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Cellmid Limited
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Dimerix Bioscience Pty Ltd
  • Dong Wha Pharma Co., Ltd.
  • Dynamis Therapeutics, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GNI Group Ltd.
  • Islet Sciences, Inc.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Mesoblast Limited
  • 田辺三菱製薬
  • MorphoSys AG
  • NephroGenex, Inc.
  • Noxxon Pharma AG
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • PhytoHealth Corporation
  • ProMetic Life Sciences Inc.
  • Serodus ASA
  • Shire Plc
  • 武田薬品工業
  • Theravance Biopharma, Inc.
  • Tobira Therapeutics, Inc.
  • Vascular Pharmaceuticals, Inc.
  • Vicore Pharma AB
  • XOMA Corporation

糖尿病性腎障害:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 11-RVIVIT
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • A-717
  • 癌用ヘパラナーゼ阻害小分子
  • APD-371
  • APX-115
  • ASP-8232
  • ATL-1103
  • 塩酸アトラセンタン
  • バリシチニブ
  • BI-703704
  • 糖尿病性腎障害向け生物製剤
  • BOT-191
  • C-21
  • カナグリフロジン
  • CCX-140 1
  • cenicriviroc mesylate
  • コルチコトロピン
  • CS-3150
  • CSL-346
  • CTP-499
  • Cyndacel-M
  • DMX-250
  • 糖尿病性心筋症・代謝性疾患向け Nrf2 活性化薬
  • DT-23552
  • DW-1029M
  • DYN-12
  • emapticap pegol
  • finerenone
  • gevokizumab
  • GKT-136901
  • GKT-831
  • GRMD-02
  • GW-610742
  • JD-5037
  • JNJ-39933673
  • リウマチ性関節炎・糖尿病合併症向け MASP-2阻害モノクローナル抗体
  • 癌・炎症性疾患・腎臓病向けミッドカイン阻害モノクローナル抗体
  • MOR-107
  • MPC-300IV
  • MT-3995
  • Nephrilin
  • oxypurinol
  • PBI-4050
  • PBI-4547
  • PF-00489791
  • PHN-033
  • pirfenidone
  • probucol
  • ピリドキサミン二塩化水素化物
  • selonsertib
  • SER-150
  • SHP-627
  • 糖尿病性腎障害向けNOX-4阻害用小分子
  • 糖尿病性腎障害向け小分子
  • 眼科学・心血管・中枢神経系・代謝性疾患向け小分子
  • 転移性癌・糖尿病性腎障害向けヘパラナーゼ阻害小分子
  • SP-20202
  • TAK-272
  • TAK-648
  • TBE-31
  • TD-0714
  • VPI-2690B
  • VS-105
  • XRX-108
  • XRX-221

糖尿病性腎障害治療薬:パイプライン製品の最新動向

糖尿病性腎障害治療薬:開発が休止状態の製品

糖尿病性腎障害治療薬:開発が中止された製品

糖尿病性腎障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Table 1: Number of Products under Development for Diabetic Nephropathy, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 6: Products under Development by Companies, H2 2019
  • Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 10: Products under Development by Universities/Institutes, H2 2019
  • Table 11: Number of Products by Stage and Target, H2 2019
  • Table 12: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 13: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 14: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 15: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 16: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 17: Number of Products by Stage and Route of Administration, H2 2019
  • Table 18: Number of Products by Stage and Molecule Type, H2 2019
  • Table 19: Diabetic Nephropathy - Pipeline by Aibios Co Ltd, H2 2019
  • Table 20: Diabetic Nephropathy - Pipeline by Algomedix Inc, H2 2019
  • Table 21: Diabetic Nephropathy - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2019
  • Table 22: Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2019
  • Table 23: Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, H2 2019
  • Table 24: Diabetic Nephropathy - Pipeline by AptaBio Therapeutics Inc, H2 2019
  • Table 25: Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2019
  • Table 26: Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2019
  • Table 27: Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2019
  • Table 28: Diabetic Nephropathy - Pipeline by Bayer AG, H2 2019
  • Table 29: Diabetic Nephropathy - Pipeline by Betagenon AB, H2 2019
  • Table 30: Diabetic Nephropathy - Pipeline by Bird Rock Bio Inc, H2 2019
  • Table 31: Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2019
  • Table 32: Diabetic Nephropathy - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Table 33: Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, H2 2019
  • Table 34: Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2019
  • Table 35: Diabetic Nephropathy - Pipeline by Certa Therapeutics Pty Ltd, H2 2019
  • Table 36: Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2019
  • Table 37: Diabetic Nephropathy - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
  • Table 38: Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2019
  • Table 39: Diabetic Nephropathy - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, H2 2019
  • Table 40: Diabetic Nephropathy - Pipeline by Curacle Co Ltd, H2 2019
  • Table 41: Diabetic Nephropathy - Pipeline by Cyclerion Therapeutics Inc, H2 2019
  • Table 42: Diabetic Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Table 43: Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2019
  • Table 44: Diabetic Nephropathy - Pipeline by Future Medicine Co Ltd, H2 2019
  • Table 45: Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2019
  • Table 46: Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2019
  • Table 47: Diabetic Nephropathy - Pipeline by Glycadia Inc, H2 2019
  • Table 48: Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2019
  • Table 49: Diabetic Nephropathy - Pipeline by Goldfinch Biopharma Inc, H2 2019
  • Table 50: Diabetic Nephropathy - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019
  • Table 51: Diabetic Nephropathy - Pipeline by Inspyr Therapeutics Inc, H2 2019
  • Table 52: Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2019
  • Table 53: Diabetic Nephropathy - Pipeline by Liminal BioSciences Inc, H2 2019
  • Table 54: Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2019
  • Table 55: Diabetic Nephropathy - Pipeline by Merck & Co Inc, H2 2019
  • Table 56: Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2019
  • Table 57: Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
  • Table 58: Diabetic Nephropathy - Pipeline by Novartis AG, H2 2019
  • Table 59: Diabetic Nephropathy - Pipeline by Novo Nordisk AS, H2 2019
  • Table 60: Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Diabetic Nephropathy, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11519IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 18, 16, 25, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Diabetic Nephropathy - Overview
  • Diabetic Nephropathy - Therapeutics Development
  • Diabetic Nephropathy - Therapeutics Assessment
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
  • Diabetic Nephropathy - Drug Profiles
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
  • Appendix
Back to Top